IM Cannabis Corp. Common Shares (IMCC)
IMCC trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1792030/000117891326001877/0001178913-26-001877-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | IMCC on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001792030 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | BC |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $38.4M |
| Net income | -$7.9M |
| Operating income | -$8.1M |
| Net margin | -20.7% |
| Operating margin | -21.2% |
| Revenue growth | +1.3% |
| Cash | $1.9M |
| Total assets | $22.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.0× |
Reported in CAD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about our ability to continue as a going concern." | 20-F 2026-03-30 |
| Cash and burn | 2.7M CAD cash; operating cash flow 1.2M CAD a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-30 on 2026-08-27 | Source 2026-08-27 |
| Shelf and offerings, 12 months | 4 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-09-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Fahn Kanne & Co., Tel-Aviv, Israel | PCAOB Form AP 2026-04-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 54.7M CAD | -11.3M CAD | 4.7M CAD | 2.7M CAD | 15.3M CAD | 54.7M CAD | 20-F 2026-03-30 |
| FY 2024 2024-12-31 | 54.0M CAD | -10.6M CAD | -1.1M CAD | 863K CAD | 15.6M CAD | 54.0M CAD | 20-F 2026-03-30 |
| FY 2023 2023-12-31 | 48.8M CAD | -9.5M CAD | -8.1M CAD | 1.8M CAD | 12.5M CAD | 48.8M CAD | 20-F 2026-03-30 |
| FY 2022 2022-12-31 | 54.3M CAD | -188.9M CAD | -12.6M CAD | 2.4M CAD | 9.6M CAD | 54.3M CAD | 20-F 2025-03-31 |
| FY 2021 2021-12-31 | 34.1M CAD | -17.8M CAD | -34.4M CAD | 13.9M CAD | 9.9M CAD | 34.1M CAD | 20-F 2024-03-28 |
| FY 2020 2020-12-31 | 15.9M CAD | -28.7M CAD | -7.9M CAD | 8.9M CAD | 0 CAD | 15.9M CAD | 20-F 2023-03-29 |
| FY 2019 2019-12-31 | 9.1M CAD | -7.3M CAD | -6.0M CAD | 13.9M CAD | No debt tags | 9.1M CAD | 40-F/A 2021-05-19 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CAD.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2026-11-10 |
| Latest annual report | 20-F | 2026-03-30 |
| Latest quarterly / interim | 6-K | 2026-11-13 |
Source: SEC EDGAR submissions feed, 307 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.0% |
| 1 month | -58.2% |
| 3 months | -85.4% |
| Year to date | -98.6% |
| 1 year | -98.6% |
| From 52-week high | -99.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| XXII | 22nd Century Group Inc. | $0.4932 | -35.96% | $272K |
| AKAN | Akanda Corp. Common Shares | $2.21 | +62.50% | $5.3M |
| NAII | Natural Alternatives International Inc. | $0.9700 | +0.35% | $6.1M |
| MTEX | Mannatech Incorporated | $3.76 | -40.32% | $7.3M |
| BON | Bon Natural Life Limited | $1.09 | -0.91% | $8.9M |
| BTMD | Biote Corp. | $0.9603 | -9.83% | $34.5M |
| FTLF | FitLife Brands Inc. | $6.83 | -19.46% | $64.1M |
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier